• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceutical Industry in United States: Industry Analysis, Forecast, Competition Mapping and Market Trends Assessment, 2011-2015 Product Image

Pharmaceutical Industry in United States: Industry Analysis, Forecast, Competition Mapping and Market Trends Assessment, 2011-2015

  • Published: June 2011
  • Region: North America, United States
  • 78 Pages
  • Indagatio Research

This report analyses the U.S. pharmaceutical industry, its historical performance and future trends for various segments as well as overall market.

Competitive analysis of leading companies is presented with focus on threats from generics. Supply chain analysis of the U.S. pharmaceutical industry is given in detail. Also covered are the market trends, growth drivers and constraints, and an assessment of M&A activity in recent years.

The United States spends more than any other country in the world on healthcare, at an estimated 16% of GDP in 2010. Healthcare expenditure is likely to continue to grow at a faster pace than overall GDP, so that its share in GDP is likely to continue to rise. In March 2010 the president, Barack Obama, signed into law a wide-ranging package of healthcare reforms, which extends insurance to around 45.7 million residents without health insurance cover.

These reforms are still encountering strong opposition, however, while another major challenge, the long-term costs of the public healthcare programs in the context of an ageing society, has not yet been addressed. Vested interests and conflicting objectives of cost-cutting and raising READ MORE >

1. Introduction
- Key Takeaways
- Research Methodology
- Industry Definition

2. U.S. Healthcare Sector

3. Industry Overview
- Global Pharmaceutical Industry
- U.S. Pharmaceutical Industry
- Industry Segmentation
- Oncologies
- Respiratory
- Lipid Regulators
- Anti-Diabetes
- Anti-Psychotic
- Industry Forecast

4. Generic Drugs Market Assessment
- Legislative Origin of Generic Drugs
- Generic Drug Pricing
- Generic Industry Trends
- API Manufacturing Industry

5. Distribution and Supply Chain Analysis
- Pharmaceutical Manufacturers
- Wholesale Distributors
- Pharmacies
- Pharmacy Benefit Managers (PBMs)

6. Trend Analysis
- Generics Market Continues to Evolve
- Soaring Prices of Branded Prescription Drugs
- Growth in R&D Spending
- Growing Pharmaceutical Outsourcing Market
- Focus on Pharmerging or Emerging Markets
- Growing Trends towards IT Outsourcing

7. Growth Drivers and Constraints
- Patents and Intellectual Property Rights
- Competition from International Players
- Industry Consolidation
- Aging Populations
- Technological Developments
- Changing Consumer Profile and Decreasing Influence
- Liability Issues
- Corporate Social Responsibility

8. Government Policies and Regulations
- Healthcare Reforms of 2010
- Health Care and Education Reconciliation Act of 2010
- Expanded & Improved Medicare for All Act (H.R. 676)
- FDA Approvals Process
- Drug Price Competition and Patent Term Restoration Act
- Regulation for Drug Distribution
- Import and Re-Import of Prescription Drugs

9. Competitive Landscape
- Competition Overview
- Analysis of Key Players
- Pfizer Inc.
- Merck & Co., Inc.
- AstraZeneca Plc
- Novartis AG
- Eli Lilly & Co.

10. Mergers & Acquisitions Assessment

List of Figures

Figure 1: Global Pharmaceutical Industry Size in USD Billion, 2000-2010
Figure 2: Market Share of Leading Pharmaceutical Markets, 2009
Figure 3: U.S. Pharmaceutical Industry Size in USD Billion, 2001-2010
Figure 4: U.S. Sales Volume of Oral Standard Units and Injectable Standard Units, 2006-2010
Figure 5: U.S. Prescriptions Pharmaceutical Volume Sales in Billion, 2001-2010
Figure 6: U.S. Pharmaceutical Industry by Leading Therapy Classes, 2010
Figure 7: U.S. Sales of Oncolocgy Drugs in USD Billion, 2006-2010
Figure 8: U.S. Sales of Respiratory Drugs in USD Billion, 2006-2010
Figure 9: U.S. Sales of Lipid Regulating Drugs in USD Billion, 2006-2010
Figure 10: U.S. Sales of Anti-Diabetes Drugs in USD Billion, 2006-2010
Figure 11: U.S. Sales of Anti-Psychotic Drugs in USD Billion, 2006-2010
Figure 12: Forecast for U.S. Pharmaceutical Industry in USD Billion, 2006-2015
Figure 13: Change in Average Relative Price of Drug with Increase in Generic Competition
Figure 14: U.S. Generic Drugs Market in USD Billion, 2005-2010
Figure 15: Shipment of Drugs Through the Supply Chain (% of Dollar Value)
Figure 16: Top Pharmaceutical Wholesale Distributors, by Revenue in USD Billion, 2010
Figure 17: Market Share of U.S. Pharmaceutical Sales by Retail Channel, 2010
Figure 18: Market Share of U.S. Prescription Drugs Sales Volume by Retail Channel, 2006-2010
Figure 19: Top Pharmaceutical Retailers by Revenue in USD Billion, 2010
Figure 20: Share of Generic Drugs in U.S. Pharmaceutical Market, 2005-2010
Figure 21: Change in The Prices of Branded Drugs Compared to Inflation, 2005-2009
Figure 22: Average Traditional Gross Cost per Prescription, 2008-2009
Figure 23: Price Inflation of Top 10 Drugs in 2009
Figure 24: U.S. Pharmaceutical R&D Spending in USD Billion, 2005-2010
Figure 25: Top Companies by Global R&D Spending in USD Billion, 2010
Figure 26: U.S. Old Population (65+ Years) Trends, 2000-2050
Figure 27: Top 10 Pharmaceutical Companies by U.S. R&D Spending in USD Billion, 2010
Figure 28: Merck's Revenues and Net Income in USD Billion, 2006-2010

List of Tables

Table 1: Healthcare Spending as a Percentage of GDP in Selected Countries, 2006-2015
Table 2: U.S. Healthcare Sector – Key Indicators and Statistics, 2006-2015
Table 3: Top 15 Therapeutic Classes by U.S. Sales in USD Billion, 2006-2010
Table 4: Top 15 Therapeutic Classes by Prescriptions Dispensed Volume in Million, 2006-2010
Table 5: Top 20 Drugs by U.S. Sales in USD Billion, 2006-2010
Table 6: U.S. Pharmaceutical Sales by Retail Channel in USD Billion, 2006-2010
Table 7: Market Share of PBM Companies by Annual Prescription Volume, 2010
Table 8: R&D Spending Growth of Leading Pharmaceutical Companies, 2006-2010
Table 9: Patents Expiry of Major Drugs in 2011-2012
Table 10: Impact of Patent Expiry over Next 3 Years on Major Players
Table 11: U.S. Pharmaceutical Companies by Sales in USD Billion, 2006-2010
Table 12: Pfizer's Revenues by Business Segments and Geographic Areas, 2008-2010
Table 13: Pfizer's Revenue for Biopharmaceutical Segment, 2008-2010
Table 14: Pfizer's Revenues of Major Drugs, 2008-2010
Table 15: Merck's Pharmaceutical Revenues by Therapeutic Areas and Products, 2008-2010
Table 16: AstraZeneca's Revenue by Therapeutic Area and Products, 2008-2010
Table 17: Novartis' Revenues by Therapeutic Areas and Products, 2009-2010
Table 18: Eli Lilly's Revenue by Products, 2009-2010
Table 19: Eli Lilly's Revenue by Therapeutic Areas, 2008-2010
Table 20: M&A Activity in U.S. Pharmaceutical Industry, 2009-2010

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos